Skip to main content

Market Overview

UPDATE: Credit Suisse Initiates BioMarin Pharmaceutical at Neutral on Revenue Growth Forecast

Share:

In a report published Friday, Credit Suisse analyst Lee Kalowski initiated coverage on BioMarin Pharmaceutical (NASDAQ: BMRN) with a Neutral rating and $68.00 price target.

In the report, Credit Suisse noted, “BMRN has a numerically impressive pipeline; we forecast revenues growing from around $550M currently to $2.3B by 2020. Our out-year revenue forecasts exceed consensus, likely due to the contribution that we model from the pipeline. We are meaningfully above the Street on operating expenses, which impacts our DCF-derived target price. We arrive at a value of $68, putting fair value at around the current stock price. We model Vimizim (MPS IVA) and PEG-PAL (PKU) with no risk weight and BMN-701 (Pompe), BMN-673 (cancer), and BMN-111 (dwarfism) with risk adjustments of 70%, 50%, and 33%, respectively. We expect Vimizim to be launching in early 2014, but the next pivotal data for BMRN is likely not due until around late 2014. We forecast $573M for Vimizim in 2020, in-line with guidance and consensus. We expect a tempered launch (2014: $74M) as ex-US reimbursement is secured; this seems to be increasingly appreciated by the Street.”

BioMarin Pharmaceutical closed on Thursday at $63.85.

Latest Ratings for BMRN

DateFirmActionFromTo
Mar 2021Canaccord GenuityMaintainsBuy
Mar 2021Evercore ISI GroupUpgradesIn-LineOutperform
Nov 2020SVB LeerinkReiteratesOutperform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

 

Related Articles (BMRN)

View Comments and Join the Discussion!

Posted-In: Credit Suisse Lee KalowskiAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com